Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25452815 | 0.82 | STS (0.51) | GPR119STS | |
| SCHEMBL25452849 | 0.81 | USP30 (0.44) | GPR119UCHL1STS | |
| SCHEMBL26611134 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL30662884 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL14831804 | 0.73 | PDK2 (0.41) | HSD11B1HTR1F | |
| SCHEMBL3520875 | 0.73 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL3520871 | 0.73 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL12094654 | 0.72 | GPR119 (0.50) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL30662893 | 0.72 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL26604392 | 0.72 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD11B1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4511128-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12195465-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-119095849-A | Macrocyclic heterocycles and uses thereof | 金橘生物科技公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208975-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885 |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | CHRM2 3897/4885CHRM1 4219/4885CHRM3 3783/4885 |
| US-12195465-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | CHRM2 4879/4885CHRM1 4884/4885CHRM3 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.